Form 4: Neogenomics Executive Warren Stone Reports Stock and Options Grants
SEC Form 4 Filing
Warren Stone, Chief Commercial Officer of Neogenomics, reports the grant of restricted stock units and details existing stock options and performance stock units.
Summary
- Warren Stone, Chief Commercial Officer of Neogenomics, filed a Form 4 detailing changes in beneficial ownership.
- The report includes the grant of 59,382 restricted stock units on January 14, 2025, which vest over time.
- It also details existing stock options with exercise prices ranging from $11.21 to $19.65 and various vesting schedules.
- The report mentions performance stock units that may vest based on share and revenue growth goals.
- Mr. Stone directly owns 84,822 shares of common stock.
Sentiment
Score: 7
Explanation: The document is a routine filing detailing executive compensation. The sentiment is neutral to slightly positive as it indicates continued alignment of management with company goals through equity ownership.
Positives
- The granting of restricted stock units and performance stock units aligns Mr. Stone's interests with the company's long-term performance.
- The vesting schedules of the stock options and restricted stock units encourage continued service with the company.
Future Outlook
The vesting of performance stock units is tied to the achievement of certain share and revenue growth goals, indicating a focus on future performance.
Industry Context
Stock grants and options are common in the biotech industry to incentivize executives and align their interests with shareholders.
Comparison to Industry Standards
- Stock option and RSU grants are a standard component of executive compensation packages in the biotechnology industry, similar to companies like Exact Sciences and Guardant Health.
- The vesting schedules described are typical, often spanning three to four years to encourage long-term commitment.
Stakeholder Impact
- Shareholders may view the equity grants as a positive sign, aligning management's interests with the company's performance.
- Employees may be motivated by the potential for future equity grants and the company's focus on growth.
Key Dates
| Date | Description |
|---|---|
| 12/01/2022 | Mr. Stone was granted 166,113 stock options. |
| 05/11/2023 | Mr. Stone was granted 53,969 stock options, 28,838 restricted stock units, and 21,204 performance stock units. |
| 02/23/2024 | Mr. Stone was granted 42,344 stock options, 25,329 restricted stock units, and 25,330 performance stock units. |
| 05/02/2024 | Mr. Stone was granted 29,976 stock options, 17,905 restricted stock units, and 17,908 performance stock units. |
| 01/14/2025 | Date of the earliest transaction reported; Mr. Stone was granted 59,382 restricted stock units. |
| 01/13/2026 | Expiration date for the restricted stock units granted on 01/14/2025. |
| 05/11/2026 | Expiration date for the performance stock units granted on 05/11/2023. |
| 02/23/2027 | Expiration date for the performance stock units granted on 02/23/2024. |
| 05/02/2027 | Expiration date for the performance stock units granted on 05/02/2024. |
| 12/01/2029 | Expiration date for stock options granted on 12/01/2022. |
| 05/11/2030 | Expiration date for stock options granted on 05/11/2023. |
| 02/23/2034 | Expiration date for stock options granted on 02/23/2024. |
| 05/02/2034 | Expiration date for stock options granted on 05/02/2024. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.